Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
 1 a 14 de 14 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S, COMPASS Investigators. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology 2019;157:agosto. [Ref.ID 103177]
2.Enlace a cita original Cita con resumen
Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, Rojas-Fernández C, Walsh K, Welch V, Moayyedi P. Deprescribing proton pump inhibitors. Evidence-based clinical practice guideline. Canadian Family Physician - Le Médecin de Famille Canadien 2017;63:354-64. [Ref.ID 101592]
3.Tiene citas relacionadas Cita con resumen
Jankowski J, Barr H, Moayyedi P. Does aspirin really reduce the risk of colon cancer?. Lancet 2012;379:1586. [Ref.ID 92734]
5. Cita con resumen
Moayyedi P, Jankowski JA. Does long term aspirin prevent cancer?. BMJ 2011;342:5-6. [Ref.ID 89997]
6.Tiene citas relacionadas
Ford AC, Talley NJ, Spiegel BMR, Foxx-Orenstein AE, Schiller L, Quigley EMM, Moayyedi P. Efficacy of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008;337:1388-92. [Ref.ID 84754]
7.Tiene citas relacionadas Cita con resumen
Delaney BC, Qume M, Moayyedi P, Logan RFA, Ford AC, Elliott C, McNulty C, Wilson S, Hobbs FDR. Helicobacter pylori and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ 2008;336:651-4. [Ref.ID 82537]
8. Cita con resumen
Moayyedi P. Sequential regimens for Helicobacter pylori eradication. Lancet 2007;370:1010-2. [Ref.ID 81099]
9.Tiene citas relacionadas Cita con resumen
Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet 2006;367:2086-100. [Ref.ID 77313]
10.Tiene citas relacionadas
Delaney B, Moayyedi P. Eradicating H pylori. BMJ 2004;328:1388-9. [Ref.ID 70332]
11.Tiene citas relacionadas Cita con resumen
Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, Delaney B, on behalf of the Dyspepsia Review Group. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. BMJ 2000;321:659-64. [Ref.ID 52822]
12. Cita con resumen
Moayyedi P, Feltbower R, Brown J, Mason S, Nathan J, Richards I D G, Dowell AC, Axon ATR, for the Leeds HELP Study Group. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Lancet 2000;355:1665-9. [Ref.ID 50953]
13.Tiene citas relacionadas
Delaney B, Moayyedi P, Soo S, Deeks J, Forman D. Will eradication of Helicobacter pylori improve symptoms of non-ulcer dyspepsia? This meta-analysis is potentially misleading. BMJ 2000;320:1208-9. [Ref.ID 50675]
14.
Moayyedi P, Carter AM, Catto A, Heppell RM, Grant PJ, Axon ATR. Validation of a rapid whole blood test for diagnosing Helicobacter pylori infection. BMJ 1997;314:119. [Ref.ID 30893]
Seleccionar todas
 
 1 a 14 de 14